2009 Leads Networking 
Clarivate
OCTOBER 31, 2023
China has emerged as a leading science and technology power on the global stage, rivaling western nations including the U.S. It shows an acceleration in published research output, which increased five-fold between 2009 and 2021, well outpacing the U.S. Our analysis suggests this trajectory is likely to continue. research landscape.
pharmaphorum
JANUARY 24, 2023
Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. Established trends are unfortunately firmly in the wrong direction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
OCTOBER 3, 2023
Established in 2009, the Trailblazer Awards recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences. Diversity/Multicultural: Anna Czene, Vice President, Corporate Communications & DEI Lead, CareDx, Inc.
Legacy MEDSearch
JUNE 16, 2023
” The pro disc C Vivo system has been in clinical use internationally since 2009 and is currently one of the most frequently implanted TDR devices in the world. I’ve found that pro disc C Vivo and pro disc C SK provide a powerful means to customize my surgical treatment to each patient.”
pharmaphorum
JULY 5, 2022
Within those, two things are critical for him: helping NICE become the “world class benchmark agency for HTA”, and a focus on ‘disease missions’ that bring together digital technology with the NHS’s network. Reducing complexity across the NHS.
Medico Reach
FEBRUARY 17, 2023
Employee Size: 485 employees Website URL: [link] 2009 saw the launch of MDLive. MDLive is a leading virtual on-demand healthcare service provider. Customers of PlushCare get access to virtual solutions for primary care issues as well as the option to schedule same-day appointments with in-network physicians.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Expert insights. Personalized for you.
75 
Let's personalize your content